Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 90/100

Failure Rate

30.0%

3 terminated/withdrawn out of 10 trials

Success Rate

70.0%

-16.5% vs industry average

Late-Stage Pipeline

10%

1 trials in Phase 3/4

Results Transparency

43%

3 of 7 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

7(70.0%)

Phase 3

1(10.0%)

Phase 2

1(10.0%)

Early Phase 1

1(10.0%)

10Total

Phase 1(7)

Phase 3(1)

Phase 2(1)

Early Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (10)

Showing 10 of 10 trials

NCT05764239Phase 3Terminated

Efficacy and Safety of SYNB1934 in Patients With PKU (SYNPHENY-3)

Role: lead

NCT04167137Phase 1Terminated

Safety and Tolerability of SYNB1891 Injection Alone or in Combination With Atezolizumab in Adult Participants

Role: lead

NCT04629170Phase 1Completed

Safety and Tolerability of SYNB8802 in Healthy Adult Volunteers and Adult Subjects With Enteric Hyperoxaluria

Role: lead

NCT05377112Early Phase 1Completed

Safety, Tolerability, and Pharmacodynamics of SYNB8802v1 in Subjects With History of Gastric Bypass Surgery or Short-bowel Syndrome

Role: lead

NCT05462132Phase 1Completed

Safety, Tolerability and Pharmacodynamics of SYNB1353 in Healthy Adult Volunteers

Role: lead

NCT04534842Phase 2Completed

Efficacy and Safety of SYNB1618 and SYNB1934 in Adult Patients With Phenylketonuria

Role: lead

NCT04984525Phase 1Completed

Safety and Tolerability of SYNB1934 in Healthy Adult Volunteers

Role: lead

NCT03447730Phase 1Terminated

Safety, Tolerability and Pharmacodynamics of SYNB1020

Role: lead

NCT03516487Phase 1Completed

Safety and Tolerability of SYNB1618 in Healthy Adult Volunteers and Adult Subjects With Phenylketonuria

Role: lead

NCT03179878Phase 1Completed

Safety and Tolerability of SYNB1020-CP-001

Role: lead

All 10 trials loaded